Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe Annually Subscribe Monthly
In two weeks’ time, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) will meet to discuss Lykos Therapeutics’ MDMA-assisted therapy for PTSD New Drug Application (NDA).
General Overview A CaaMTech & ASRI Collaboration GH Research & Beckley Psytech: An Update CaaMTech Grows Tryptamine Patent Portfolio Atai Sees Two New Allowances to
Despite efforts by the bill’s authors and advocates to play to the tune of state and national politics, this latest attempt at psychedelic policy reform
Featured content in this Issue: Tempering Excitement Around Recent Raises Compass Shares Cut of Open-Label PTSD Data Other Stories: We bring you up to speed
The VA has been warming up to psychedelic research and the potential roll-out of psychedelic therapies, if approved by the FDA, for the past few
Chief among the public comments was a brief submission from Lykos Therapeutics itself (page 1). “Lykos is disappointed by the ICER draft report as it
AbbVie has become the latest large pharmaceutical company to dip its toes into psychedelic drug development as it announced what might be the most substantial foray
Save the date: the FDA will hold an advisory committee meeting to review Lykos Therapeutics’ New Drug Application (NDA) for MDMA-assisted psychotherapy in the treatment of PTSD on
On Tuesday, Dr. Steffen Thirstrup, Chief Medical Officer (CMO) of the European Medicines Agency (EMA), gave a live presentation and Q&A on the topic of ‘psychedelics and